163 related articles for article (PubMed ID: 18155535)
1. Model predictive control of erythropoietin administration in the anemia of ESRD.
Gaweda AE; Jacobs AA; Aronoff GR; Brier ME
Am J Kidney Dis; 2008 Jan; 51(1):71-9. PubMed ID: 18155535
[TBL] [Abstract][Full Text] [Related]
2. Randomized trial of model predictive control for improved anemia management.
Brier ME; Gaweda AE; Dailey A; Aronoff GR; Jacobs AA
Clin J Am Soc Nephrol; 2010 May; 5(5):814-20. PubMed ID: 20185598
[TBL] [Abstract][Full Text] [Related]
3. Individualized anemia management in a dialysis facility - long-term utility as a single-center quality improvement experience
.
Gaweda AE; Jacobs AA; Aronoff GR; Brier ME
Clin Nephrol; 2018 Oct; 90(4):276-285. PubMed ID: 30049300
[TBL] [Abstract][Full Text] [Related]
4. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
5. An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting.
Patel M; Thimons DG; Winston JL; Langholff W; McGowan T
J Am Med Dir Assoc; 2012 Mar; 13(3):244-8. PubMed ID: 21450214
[TBL] [Abstract][Full Text] [Related]
6. Anemia control in renal transplant recipients receiving continuous erythropoietin receptor activator (C.E.R.A.) treatment: the AnemiaTrans Study.
Sánchez-Fructuoso AI; Ruiz JC; Torregrosa JV; González E; Gómez E; Gallego RJ; Troya MI; Jimenez C; Llamas F; Romero R; Bernis C; Crespo JF; Guirado L;
Adv Ther; 2012 Nov; 29(11):979-91. PubMed ID: 23160946
[TBL] [Abstract][Full Text] [Related]
7. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC;
Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
[TBL] [Abstract][Full Text] [Related]
8. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
Hertel J; Locay H; Scarlata D; Jackson L; Prathikanti R; Audhya P
Am J Nephrol; 2006; 26(2):149-56. PubMed ID: 16636531
[TBL] [Abstract][Full Text] [Related]
9. Assessment of erythropoietin for treatment of anemia in chronic kidney failure- ESRD patients.
Srinivasan R; Fredy IC; Chandrashekar S; Saravanan J; Mohanta GP; Manna PK
Biomed Pharmacother; 2016 Aug; 82():44-8. PubMed ID: 27470337
[TBL] [Abstract][Full Text] [Related]
10. Effects of erythropoietin on left ventricular hypertrophy in adults with severe chronic renal failure and hemoglobin <10 g/dL.
Ayus JC; Go AS; Valderrabano F; Verde E; de Vinuesa SG; Achinger SG; Lorenzo V; Arieff AI; Luño J;
Kidney Int; 2005 Aug; 68(2):788-95. PubMed ID: 16014057
[TBL] [Abstract][Full Text] [Related]
11. Dosing intervals and hemoglobin control in patients with chronic kidney disease and anemia treated with epoetin alfa or darbepoetin alfa: a retrospective cohort study.
Nurko S; Spirko R; Law A; Dennis VW
Clin Ther; 2007 Sep; 29(9):2010-21. PubMed ID: 18035200
[TBL] [Abstract][Full Text] [Related]
12. Chronic dialysis-associated anaemia in end-stage renal disease: analysis of management in two French centres.
Perrinet M; Décaudin B; Champs BB; Heran I; Urbina MA; Lemaitre V; Azar R; Odou P
J Clin Pharm Ther; 2010 Aug; 35(4):395-400. PubMed ID: 20831542
[TBL] [Abstract][Full Text] [Related]
13. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F
Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
[TBL] [Abstract][Full Text] [Related]
14. Changes in hemoglobin level distribution in US dialysis patients from June 2006 to November 2008.
Spiegel DM; Khan I; Krishnan M; Mayne TJ
Am J Kidney Dis; 2010 Jan; 55(1):113-20. PubMed ID: 19932539
[TBL] [Abstract][Full Text] [Related]
15. Clinical impact of the ERBP Working Group 2010 Recommendations for the anemia management in chronic kidney disease not on dialysis: ACERCA study.
Martínez-Castelao A; Cases A; Carballada AT; Iranzo JT; Bronsoms J; Vallès-Prats M; Monserrat DT; Jimenez EM;
Nefrologia; 2015; 35(2):179-88. PubMed ID: 26300512
[TBL] [Abstract][Full Text] [Related]
16. Darbepoetin alfa once monthly corrects anaemia in patients with chronic kidney disease not on dialysis.
Roger SD; Kolmakova E; Fung M; Malecki R; Vinhas J; Dellanna F; Thomas M; Manamley N; Ferenczi S
Nephrology (Carlton); 2014 May; 19(5):266-74. PubMed ID: 24506498
[TBL] [Abstract][Full Text] [Related]
17. [Combined therapy with L-carnitine and erythropoietin of anemia in chronic kidney failure patients undergoing hemodialysis].
Wanic-Kossowska M; Kazmierski M; Pawliczak E; Kobelski M
Pol Arch Med Wewn; 2007; 117(1-2):14-9. PubMed ID: 17642201
[TBL] [Abstract][Full Text] [Related]
18. Once-monthly darbepoetin alfa for maintaining hemoglobin levels in older patients with chronic kidney disease.
Agarwal A; Silver MR; Walczyk M; Liu W; Audhya P
J Am Med Dir Assoc; 2007 Feb; 8(2):83-90. PubMed ID: 17289537
[TBL] [Abstract][Full Text] [Related]
19. Low hemoglobin levels and hypo-responsiveness to erythropoiesis-stimulating agent associated with poor survival in incident Japanese hemodialysis patients.
Akizawa T; Saito A; Gejyo F; Suzuki M; Nishizawa Y; Tomino Y; Tsubakihara Y; Akiba T; Hirakata H; Watanabe Y; Kawanishi H; Bessho M; Udagawa Y; Aoki K; Uemura Y; Ohashi Y;
Ther Apher Dial; 2014 Oct; 18(5):404-13. PubMed ID: 24571446
[TBL] [Abstract][Full Text] [Related]
20. Hemoglobin level variability in hemodialysis patients treated with epoetin-β during 1 year.
Kessler M; Landais P; Bataille P; Yver L; Koné S; Kraemer S; Brillet G; Canivet E
Clin Nephrol; 2011 Sep; 76(3):210-7. PubMed ID: 21888858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]